Orthopaedic Spine Department, Second Xiangya Hospital, Central South University, Chanhsha, China.
Spine (Phila Pa 1976). 2013 May 1;38(10):806-13. doi: 10.1097/BRS.0b013e31827eca09.
In vivo rodent model.
Investigate the effect of systemic corticosteroid administration on soft-tissue inflammation after local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2).
Corticosteroid use in cases of soft-tissue inflammation associated with the use of rhBMP-2 has been reported in clinical studies, but the effectiveness of its use and appropriate timing remain unclear.
Absorbable collagen sponges were implanted with control or rhBMP-2 into the lumbar region of rats subcutaneously and intramuscularly. Four groups were studied: group I, control sponge only; group 2, BMP-2 sponge only; group III, BMP-2 sponge and preoperative intraperitoneal methylprednisolone (MPSS); group IV, BMP-2 sponge with MPSS given on day 2. Using magnetic resonance imaging, inflammation was assessed in terms of soft tissue edema volume at 0, 2, 4, and 7 days. Rats were sacrificed after 7 days for gross and histological analysis.
The peak mean intramuscular inflammatory volume occurred on day 2 in all groups. Group II (BMP-2 without MPSS) had a significantly higher peak mean inflammatory volume (405.46 mm) on day 2 than that of groups I (266 mm), III (278 mm), and IV (291 mm) (P = 0.001). No significant difference in intramuscular soft-tissue inflammation was observed between the control group and the groups receiving MPSS on day 0 or day 2 at any time point. No differences in the area of inflammatory cell infiltrate surrounding the sponge was observed histologically, after sacrificing them, in groups treated with BMP-2.
Systemic MPSS administration reduced soft tissue edema associated with rhBMP-2 as measured by magnetic resonance imaging, but no effect was observed on the histological area of inflammation. Further studies are required to elucidate if there is any benefit to the use of corticosteroid administration in reducing the area of inflammation associated with the use of rhBMP-2.
体内啮齿动物模型。
研究全身皮质类固醇给药对局部给予重组人骨形态发生蛋白-2（rhBMP-2）后软组织炎症的影响。
在 rhBMP-2 相关软组织炎症的临床研究中已报道皮质类固醇的使用，但使用的有效性和适当的时机仍不清楚。
将可吸收胶原海绵植入大鼠皮下和肌肉内的对照或 rhBMP-2 中。研究了 4 组：组 I，仅对照海绵；组 2，仅 BMP-2 海绵；组 3，BMP-2 海绵和术前腹腔内甲泼尼龙（MPSS）；组 4，第 2 天给予 BMP-2 海绵和 MPSS。使用磁共振成像，在 0、2、4 和 7 天评估软组织水肿体积的炎症。第 7 天处死大鼠进行大体和组织学分析。
所有组的肌肉内炎症体积峰值均出现在第 2 天。组 2（无 MPSS 的 BMP-2）在第 2 天的峰值平均炎症体积（405.46mm）明显高于组 I（266mm）、组 3（278mm）和组 4（291mm）（P=0.001）。在任何时间点，接受 MPSS 的对照组和第 0 天或第 2 天的组之间，肌肉内软组织炎症无显著差异。在处死它们后，用 BMP-2 治疗的组中，海绵周围炎症细胞浸润的区域在组织学上没有差异。
全身 MPSS 给药减少了 rhBMP-2 引起的磁共振成像软组织水肿，但对炎症面积没有影响。需要进一步研究以阐明皮质类固醇给药在减少 rhBMP-2 相关炎症面积方面是否有益。
